Top Page
dorsaVi Limited
(Sydney:DVL)
dorsaVi Limited (DVL) vs. iShares MSCI Australia ETF (EWA)
dorsaVi Limited Business Overview & Revenue Model
dorsaVi Limited Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.30M | 1.75M | 2.35M | 1.87M | 2.02M |
| Gross Profit | 1.18M | -798.43K | -1.45M | -1.74M | -2.21M |
| EBITDA | -1.60M | -1.88M | -1.53M | -2.29M | -6.84M |
| Net Income | -1.25M | -1.82M | -1.54M | -2.41M | -7.59M |
Balance Sheet | |||||
| Total Assets | 2.18M | 2.69M | 3.36M | 5.42M | 3.83M |
| Cash, Cash Equivalents and Short-Term Investments | 478.10K | 878.72K | 449.70K | 2.80M | 1.69M |
| Total Debt | 190.17K | 321.85K | 1.18M | 1.18M | 1.91M |
| Total Liabilities | 1.16M | 1.01M | 2.13M | 2.95M | 3.37M |
| Stockholders Equity | 1.02M | 1.68M | 1.22M | 2.48M | 459.03K |
Cash Flow | |||||
| Free Cash Flow | -622.08K | -1.02M | -2.25M | -2.36M | -2.97M |
| Operating Cash Flow | -600.90K | -967.41K | -2.15M | -2.27M | -2.18M |
| Investing Cash Flow | -21.18K | -51.65K | -100.34K | -85.41K | -788.80K |
| Financing Cash Flow | 227.06K | 1.45M | -92.25K | 3.47M | 1.89M |
dorsaVi Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | €9.09B | 16.74 | 4.09% | 1.84% | 4.14% | -26.32% | |
53 Neutral | AU$11.23M | ― | -127.39% | ― | -17.08% | -2263.16% | |
48 Neutral | AU$4.09M | ― | -637.73% | ― | -13.05% | -184.09% | |
45 Neutral | AU$22.78M | ― | -74.01% | ― | -8.28% | 35.71% | |
42 Neutral | AU$9.14M | ― | -1370.92% | ― | -36.98% | 41.43% | |
41 Neutral | AU$4.90M | ― | -174.80% | ― | -50.78% | 45.67% | |
39 Underperform | AU$11.14M | ― | -50.47% | ― | -31.53% | -31.70% |
dorsaVi Limited Corporate Events
dorsaVi Limited has announced breakthrough results from its evaluation of RRAM-enabled biomedical sensors, highlighting significant improvements in speed, endurance, and energy consumption metrics. The integration of RRAM technology into dorsaVi’s platforms promises enhanced performance for wearable biomedical devices, offering faster memory access, lower power consumption, and greater endurance, which are crucial for real-world clinical and movement-monitoring applications.
dorsaVi Limited has announced that its 2025 Extraordinary General Meeting will be held virtually on August 15, 2025. Shareholders are encouraged to vote by proxy and submit questions in advance, with the company prepared to make alternative arrangements if necessary. This move reflects the company’s adaptability in managing shareholder engagement and maintaining transparency in its operations.
dorsaVi Limited has announced an Extraordinary General Meeting to be held virtually on August 15, 2025, where shareholders will vote on key resolutions, including the ratification of prior issues of Tranche 1 Placement Shares. This meeting reflects the company’s ongoing efforts to engage shareholders in its strategic decisions and ensure compliance with regulatory requirements, which could impact its financial positioning and stakeholder relations.
dorsaVi Limited has announced the validation and integration of its licensed Resistive Random-Access Memory (RRAM) technology, which is expected to significantly enhance the performance of its sensor platforms. The RRAM technology offers high-speed, low-power capabilities suitable for next-generation embedded and edge AI platforms, with potential applications in robotics, adaptive sensing, and advanced edge-AI systems. This advancement positions dorsaVi to lead in real-time movement analysis and explore new markets through strategic partnerships.
DorsaVi Limited announced the cessation of 3,693,714 securities due to the expiry of options or other convertible securities without exercise or conversion. This cessation may impact the company’s issued capital and could have implications for stakeholders regarding the company’s financial structure and market activities.
dorsaVi Limited announced that Dr. Michael Winlo has ceased to be a director of the company as of July 3, 2025. The announcement details Dr. Winlo’s holdings in the company, which include 3,251,940 quoted shares and 454,545 unlisted options. This change in directorship may impact the company’s governance and strategic direction, influencing stakeholders’ perceptions and potentially affecting its market positioning.
dorsaVi Limited has initiated testing of its RRAM-powered sensor systems in Singapore, marking a significant step in integrating next-generation Resistive Random-Access Memory into its biomedical sensor platforms. This development is expected to enhance the speed and efficiency of applications like EMG and ECG, addressing limitations of traditional memory systems. The results from this testing will inform potential scaling strategies for various biomedical sensors and open opportunities in AI, robotics, and neuromorphic computing, reinforcing dorsaVi’s leadership in the industry.
dorsaVi Limited has announced the issuance of 70,000,000 fully paid ordinary shares, as per the Corporations Act 2001. This move complies with all necessary legal provisions and indicates the company’s ongoing transparency and adherence to regulatory requirements. The issuance of shares could potentially enhance dorsaVi’s financial capabilities, supporting its operations in the motion analysis technology sector and possibly impacting its market position positively.
DorsaVi Limited has announced the quotation of 70 million fully paid ordinary securities on the Australian Securities Exchange (ASX) as of July 4, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and offering new opportunities for stakeholders.
dorsaVi Limited has announced a change in the interests of its director, Andrew James Ronchi. The update involves the conversion of 500,000 performance rights into shares, increasing his indirect holdings while the performance rights lapsed. This change reflects an internal adjustment in the director’s securities, potentially impacting the company’s governance and shareholder dynamics.
dorsaVi Ltd announced the resignation of Mr. Michael Winlo as Non-Executive Director to focus on other business commitments. The company is shifting its strategic focus to hiring executives and advisers with expertise in RRAM and semiconductor technologies, which is expected to enhance the performance of their sensors. This move is part of dorsaVi’s plan to drive innovation and growth, with the Non-Executive Chairman expressing excitement about the potential of RRAM technology to improve sensor performance.
dorsaVi Limited has issued 109,959,038 fully paid ordinary shares without disclosure to investors as per the Corporations Act. This move signifies the company’s compliance with the necessary legal provisions and indicates no excluded information under the relevant sections of the Corporations Act. The issuance of shares could potentially impact dorsaVi’s market operations and stakeholder interests by enhancing its capital structure and possibly influencing its market positioning.
DorsaVi Limited announced the cessation of 1,052,500 performance rights due to unmet conditions, effective June 27, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.
dorsaVi Limited has announced the quotation of nearly 5 million fully paid ordinary securities on the Australian Securities Exchange (ASX) as of June 27, 2025. This move is part of the company’s strategy to expand its market presence and potentially increase its capital base, which could enhance its operational capabilities and strengthen its position in the wearable sensor technology market.
dorsaVi Limited announced the quotation of 105,000,000 fully paid ordinary securities on the ASX, effective June 27, 2025. This move is part of previously announced transactions and is expected to enhance the company’s capital structure, potentially impacting its market positioning and offering new opportunities for stakeholders.
dorsaVi Limited has announced a proposed issue of 20 million new securities, specifically options expiring three years from issuance at an exercise price of $0.02. This move is part of a strategic placement aimed at enhancing the company’s financial positioning and operational capabilities, potentially impacting its market presence and offering benefits to stakeholders through increased capital resources.
dorsaVi Limited announced a proposed issue of 60,000,000 ordinary fully paid securities, with the issuance date set for August 1, 2025. This move is part of a placement or other type of issue, which may impact the company’s market positioning by potentially increasing its capital base and providing additional resources for growth and development.
dorsaVi Limited has secured an exclusive worldwide license for advanced resistive random-access memory (RRAM) technology from NTU Singapore. This strategic acquisition is set to enhance dorsaVi’s sensor technology, offering improved efficiency and extended battery life, positioning the company for growth in high-value markets such as elite sports, rehabilitation, and industrial automation. The integration of RRAM technology into dorsaVi’s products is expected to redefine wearable technology capabilities, providing a competitive edge in the industry.
dorsaVi Limited has requested a trading halt on its securities pending an important announcement regarding a Worldwide Exclusive RRAM Licence Agreement and a capital raising initiative. This move is aimed at managing its continuous disclosure obligations and is expected to impact the company’s market operations by potentially enhancing its technological capabilities and financial position.
dorsaVi has signed a three-year agreement with SANO Health, a leader in mining health solutions, to extend the use of its ViSafe+ technology across remote mining sites in Australia. This partnership aims to enhance dorsaVi’s product offerings in high-risk industries like mining and transport, allowing the company to expand its market reach both domestically and internationally, while providing SANO Health with the tools to improve workplace safety and reduce musculoskeletal injuries.
dorsaVi has expanded its AI-powered movement analysis platform, Video AI, into the workplace ergonomics market, partnering with a major US franchise group and a leading Australian insurer. This strategic move allows dorsaVi to leverage its scalable, high-margin Video AI platform to enter the multibillion-dollar workplace safety and injury prevention market, marking a significant milestone in the company’s product evolution.
dorsaVi Limited has reported significant progress in the commercial release of its AI-powered Video Movement Analysis Platform, gaining traction in the US market. The company has achieved sales revenue of $289k and is advancing security clearances with a major US clinical group, which could expand its market presence. Additionally, dorsaVi has launched a pioneering 3D motion analysis test to address ACL injuries, potentially setting a new standard in sports medicine. A new research collaboration with a prominent US surgeon aims to optimize movement analysis for elite athletes, further reinforcing dorsaVi’s leadership in data security and injury prevention.